Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics.
The human cytomegalovirus (HCMV) protease is a potential target for antiviral chemotherapeutics; however, autoprocessing at internal sites, particularly at positions 143 and 209, hinders the production of large quantities of stable enzyme for either screening or structural studies. Using peptides encompassing the sequence of the natural M-site substrate (P5-P5', GVVNA/SCRLA), we previously demonstrated that substitution of glycine for valine at the P3 position in the substrate abrogates processing by the recombinant protease in vitro. We now demonstrate that introduction of the V-to-G substitution in the P3 positions of the two major internal processing sites, positions 143 and 209, in the mature HCMV protease renders the enzyme stable to autoprocessing. When expressed in Escherichia coli, the doubly substituted protease was produced almost exclusively as the 30-kDa full-length protein. The full-length V141G, V207G (V-to-G changes at positions 141 and 207) protease was purified as a soluble protein by a simple two-step procedure, ammonium sulfate precipitation followed by DEAE ion-exchange chromatography, resulting in 10 to 15 mg of greater than 95% pure enzyme per liter. The stabilized enzyme was characterized kinetically and was indistinguishable from the wild-type recombinant protease, exhibiting Km and catalytic constant values of 0.578 mM and 13.18/min, respectively, for the maturation site (M-site) peptide substrate, GVVNASCRLARR (underlined residues indicate additions to or substitutions from peptides derived from the wild-type substrate). This enzyme was also used to perform inhibition studies with a series of truncated and/or substituted maturation site peptides. Short nonsubstrate M-site-derived peptides were demonstrated to be competitive inhibitors of cleavage in vitro, and these analyses defined amino acids VVNA, P4 through P1 in the substrate, as the minimal substrate binding and recognition sequence for the HCMV protease.
LaFemina
R L
RL
Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. robert_lafemina@merck.com
Bakshi
K
K
Long
W J
WJ
Pramanik
B
B
Veloski
C A
CA
Wolanski
B S
BS
Marcy
A I
AI
Hazuda
D J
DJ
D000595:Amino Acid Sequence; D001483:Base Sequence; D001665:Binding Sites; D003587:Cytomegalovirus / Q000201:enzymology*; D010450:Endopeptidases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D004926:Escherichia coli; D006801:Humans; D018716:Molecular Mimicry; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides; D010455:Peptides / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000302:isolation & purification; D012995:Solubility; D014764:Viral Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D009838:Oligodeoxyribonucleotides; D010455:Peptides; D011480:Protease Inhibitors; D011993:Recombinant Fusion Proteins; D014764:Viral Proteins; D010450:Endopeptidases; C087225:human cytomegalovirus protease UL80